CBS promoter hypermethylation increases the risk of hypertension and stroke

Detalhes bibliográficos
Autor(a) principal: Wang, Changyi
Data de Publicação: 2019
Outros Autores: Xu, Guodong, Wen, Qi, Peng, Xiaolin, Chen, Hongen, Zhang, Jingwen, Xu, Shan, Zhang, Chunhui, Zhang, Min, Ma, Jianping, Hui, Zhaohui, Wu, Guifu, Ma, Min
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinics
Texto Completo: https://www.revistas.usp.br/clinics/article/view/157898
Resumo: OBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2- ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients.
id USP-19_27dc0360185a46528e4d84d226313b27
oai_identifier_str oai:revistas.usp.br:article/157898
network_acronym_str USP-19
network_name_str Clinics
repository_id_str
spelling CBS promoter hypermethylation increases the risk of hypertension and strokeCBSHypermethylationHypertensionStrokeHomocysteineOBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2- ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients.Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2019-05-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/xmlhttps://www.revistas.usp.br/clinics/article/view/15789810.6061/clinics/2019/e630Clinics; Vol. 74 (2019); e630Clinics; v. 74 (2019); e630Clinics; Vol. 74 (2019); e6301980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/157898/153187https://www.revistas.usp.br/clinics/article/view/157898/153589Copyright (c) 2019 Clinicsinfo:eu-repo/semantics/openAccessWang, ChangyiXu, GuodongWen, QiPeng, XiaolinChen, HongenZhang, JingwenXu, ShanZhang, ChunhuiZhang, MinMa, JianpingHui, ZhaohuiWu, GuifuMa, Min2019-05-24T13:16:00Zoai:revistas.usp.br:article/157898Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2019-05-24T13:16Clinics - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv CBS promoter hypermethylation increases the risk of hypertension and stroke
title CBS promoter hypermethylation increases the risk of hypertension and stroke
spellingShingle CBS promoter hypermethylation increases the risk of hypertension and stroke
Wang, Changyi
CBS
Hypermethylation
Hypertension
Stroke
Homocysteine
title_short CBS promoter hypermethylation increases the risk of hypertension and stroke
title_full CBS promoter hypermethylation increases the risk of hypertension and stroke
title_fullStr CBS promoter hypermethylation increases the risk of hypertension and stroke
title_full_unstemmed CBS promoter hypermethylation increases the risk of hypertension and stroke
title_sort CBS promoter hypermethylation increases the risk of hypertension and stroke
author Wang, Changyi
author_facet Wang, Changyi
Xu, Guodong
Wen, Qi
Peng, Xiaolin
Chen, Hongen
Zhang, Jingwen
Xu, Shan
Zhang, Chunhui
Zhang, Min
Ma, Jianping
Hui, Zhaohui
Wu, Guifu
Ma, Min
author_role author
author2 Xu, Guodong
Wen, Qi
Peng, Xiaolin
Chen, Hongen
Zhang, Jingwen
Xu, Shan
Zhang, Chunhui
Zhang, Min
Ma, Jianping
Hui, Zhaohui
Wu, Guifu
Ma, Min
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Wang, Changyi
Xu, Guodong
Wen, Qi
Peng, Xiaolin
Chen, Hongen
Zhang, Jingwen
Xu, Shan
Zhang, Chunhui
Zhang, Min
Ma, Jianping
Hui, Zhaohui
Wu, Guifu
Ma, Min
dc.subject.por.fl_str_mv CBS
Hypermethylation
Hypertension
Stroke
Homocysteine
topic CBS
Hypermethylation
Hypertension
Stroke
Homocysteine
description OBJECTIVES: Cystathionine β-synthase is a major enzyme in the metabolism of plasma homocysteine. Hyperhomocysteinemia is positively associated with hypertension and stroke. The present study was performed to examine the possible effects of Cystathionine β-synthase promoter methylation on the development of hypertension and stroke. METHODS: Using quantitative methylation-specific PCR, we determined the Cystathionine β-synthase methylation levels in 218 healthy individuals and 132 and 243 age- and gender-matched stroke and hypertensive patients, respectively. The relative changes in Cystathionine β-synthase promoter methylation were analyzed using the 2- ΔΔCt method. The percent of the methylated reference of Cystathionine β-synthase was used to represent the Cystathionine β-synthase promoter methylation levels. RESULTS: In this study, the Cystathionine β-synthase promoter methylation levels of hypertensive and stroke participants were both higher than that of the healthy individuals (median percentages of the methylated reference were 50.61%, 38.05% and 30.53%, respectively, all p<0.001). Multivariable analysis showed that Cystathionine β-synthase promoter hypermethylation increased the risk of hypertension [odds ratio, OR (95% confidence interval, CI)=1.035 (1.025–1.045)] and stroke [OR (95% CI)=1.015 (1.003–1.028)]. The area under the curve of Cystathionine β-synthase promoter methylation was 0.844 (95% CI: 0.796–0.892) in male patients with hypertension and 0.722 (95% CI: 0.653–0.799) in male patients with stroke. CONCLUSION: Cystathionine β-synthase promoter hypermethylation increases the risk of hypertension and stroke, especially in male patients.
publishDate 2019
dc.date.none.fl_str_mv 2019-05-10
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/clinics/article/view/157898
10.6061/clinics/2019/e630
url https://www.revistas.usp.br/clinics/article/view/157898
identifier_str_mv 10.6061/clinics/2019/e630
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/clinics/article/view/157898/153187
https://www.revistas.usp.br/clinics/article/view/157898/153589
dc.rights.driver.fl_str_mv Copyright (c) 2019 Clinics
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Clinics
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/xml
dc.publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
publisher.none.fl_str_mv Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo
dc.source.none.fl_str_mv Clinics; Vol. 74 (2019); e630
Clinics; v. 74 (2019); e630
Clinics; Vol. 74 (2019); e630
1980-5322
1807-5932
reponame:Clinics
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Clinics
collection Clinics
repository.name.fl_str_mv Clinics - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||clinics@hc.fm.usp.br
_version_ 1800222764108349440